Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

Constipation Treatment Market Constipation Treatment Market Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Constipation Treatment - Global Strategic Business Report" has been added to ...

Researchers have discovered a new mechanism that is used by a male sex hormone essential for muscle and bone function. The ...

Researchers at the Center for Life Sciences at the Paul Scherrer Institute PSI have for the first time identified structural ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

Entero Therapeutics, Inc. (Nasdaq: ENTO) ("Entero” or the "Company”), a clinical-stage biopharmaceutical company specializing ...

China had the highest number of publications (359, 29.97%), followed by the United States (277, 23.12%), Ireland (98, 8.18%), Canada (95, 7.9%), and Italy (67, 5.59%). The top five ... terms such as ...

The Renault 5 isn’t the first car from a bygone era to make a comeback, but we reckon it could prove just as successful as other efforts (including the reimagined Fiat 500 and Mini). Indeed ...

This announcement is based on a press release statement from Silo Pharma. With a current ratio of 7.9, the company maintains strong liquidity to fund its development pipeline, though analysts tracked ...

Read on to learn everything we know about Fallout 5. If you've ever played a Fallout game, you'll know the series revels in its nuclear-ravaged American setting. Fallout games have all been set in ...

SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA’s streamlined ...

Genetic manipulation of 5-HT receptors revealed that this neuromodulatory regulation is mediated by 5-HT1a receptors and the knockdown of these receptors leads to memory impairment. Together, our ...